本文已被：浏览 5693次 下载 0次
中文摘要: 目的 分析氯沙坦与硝苯地平联合应用对高血压肾病患者的肾功能及预后影响。方法 选取2015年1月—2017年12月上海市彭浦新村街道社区卫生服务中心接诊的100例高血压肾病患者作为研究对象，随机分为三组进行对比分析，其中，A组和B组患者分别单服氯沙坦钾片和硝苯地平缓释片（III），C组联合服用氯沙坦钾片和硝苯地平缓释片（III）。观察并比较三组患者收缩压和舒张压变化情况，并对三组患者服药1周和2周后血清样本血尿素氮（BUN）、血尿酸（BUA）、血肌酐（SCr）和尿微量白蛋白（UAER）改善情况进行统计学比较分析；分析三组患者服药后疗效预后，观察不良反应。结果 三组患者用药前收缩压和舒张压差异无统计学意义（P＞0.05），治疗后C组患者收缩压和舒张压改善情况优于A组和B组，差异具有统计学意义（F=701.1500，P＜0.05；F=21.28，P＜0.05）；服药治疗1～2周后，肾功能指标（BUN、BUA、SCr和UAER）改善明显，且C组改善情况较A组和B组更趋近于标准正常值，差异具有统计学意义（P＜0.05）；结合相关指标复查进行综合评定，A组治疗有效率为72.73%（24/33），B组治疗有效率为75.76%（25/33），均低于C组94.12%（32/34），差异具有统计学意义（P＜0.05，且服药后不良症状反应率符合用药标准。结论 氯沙坦与硝苯地平联合应用降压效果显著，能有效改善肾功能，而预后综合评价疗效可靠。
Abstract:OBJECTIVE To analysis the impact of renal function and prognosis for hypertensive nephropathy combined application of losartan and nifedipine. METHODS 100 cases of patients with hypertensive nephropathy from January 2015 to December 2017 in our hospital as the research object, which were randomly divided into three groups to analysis, including A group and B group were taking Losartan Potassium Tablets and Extended Release Nifedipine Tablets (III), C group were combined to use Losartan Potassium Tablets and Extended Release Nifedipine Tablets (III). The systolic and diastolic blood pressure changes were observed and compared for the three groups, after 1 weeks and 2 weeks the serum blood urea nitrogen (BUN), blood uric acid (BUA), serum creatinine (SCr) and urinary albumin (UAER) were analyzed to improve the situation; The efficacy and prognosis of the three groups were analyzed and the adverse reactions were observed.RESULTS There was no significant difference in systolic and diastolic blood pressure between the three groups before treatment (P＞0.05). The improvement of systolic and diastolic blood pressure in the C group was better than that A group and B group in the treatment group, and the difference was statistically significant（F=701.1500，P＜0.05；F=21.28，P＜0.05）; After 1~2 weeks of treatment, the renal function indexes (BUN, BUA, SCr, UAER) improved obviously, and the improvement of C group was closer to the standard normal value than A group and B group, and the difference was statistically significant(P＜0.05)；Combined with the relevant indicators review a comprehensive
assessment of the effective rate of A group was 72.73% (24/33), the effective rate of B group was 75.76% (25/33), were lower than those in group C (32/34 94.12%), the difference was statistically significant (P＜0.05), and medication adverse reaction rate in line with the standard treatment of symptoms. CONCLUSION The combined use of losartan and nifedipine is effective and to improve renal function, while the prognosis is reliable.
文章编号：3201812027 中图分类号：R544.1 文献标志码：
基金项目:
| 作者 | 单位 |
| 张莉芳① |
| Author Name | Affiliation |
引用文本：